Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production. Its work centers on disease areas where insufficient protein activity plays a key role, including disorders affecting the liver and central nervous system. Camp4 Therapeutics Corporation’s current pipeline includes product candidates for urea cycle disorders and SYNGAP1-related disorders, reflecting its focus on rare and genetically driven conditions. Based in Cambridge, Massachusetts, the company operates within the biotechnology sector and contributes to the broader effort to create targeted treatments for inherited diseases through RNA modulation.
WebsiteOne Kendall Square
Cambridge, MA, 02139
United States
CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028. The company’s analyst event focused on CMP-002, an antisense oligon
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company anticipates initiation of the clinical trial in 4Q 2026 WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics design
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadersh
Investors talking about CAMP also mention
What share of all stock conversation is about CAMP?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about CAMP that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% 0 | 92.04% +5.42 | ||
| Bearish | — | — | 0% 0 | 7.96% -5.42 |
Of the messages about CAMP that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 100% | 25.41% | ||
| Earnings | — | — | 0% | 57.57% | ||
| Analysts | — | — | 0% | 4.32% | ||
| Controversies | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 0% | ||
| Technical Analysis | — | — | 0% | 12.7% |
Of the messages about CAMP, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 6.19% | ||
| Newcomers | — | — | 100% | 93.81% |